Wuxi Apptec just reported 3Q26, at a first glance all seems fine: --FY revenue growth guide moved up from 37% to 41% (expected I think) --Backlog up from rmb66bn in June to 77bn in September (up 36% YTD, from up 25% 1H26) --CF up 70%, capex guide up, EBIT margin flattish 45%, blah blah.. --BUT...MOST important...and after keeping silent quarter after quarter...we finally get an 🥁 "AI drug discovery" mention in the report. Wow. They really can keep up with the times. Imagine also Wuxi management this summer watching Genscript share price moon thinking "seriously? these guys?" Actually we get two: AIDD and AI4S. Check out the prose, it's exquisite: "We efficiently fulfill the rapidly growing demand from global AIDD/AI4S customers for dry & wet lab closed-loop R&D, further solidifying our industry leading position. We continue to enhance AI and automation capabilities, enabling multiple use cases in pharmacology, pathology, and beyond. In response to the needs of AIDD/AI4S customers, we provide high-throughput, diverse, customized, comprehensive, and integrated wet lab services, fostering novel partnerships with high efficiency and synergy."🥲 What does it mean? No one knows what it means, but it's provocative... it gets the people going... let's see how this mixes with a gigabear market out there yours for 17x LTM EV EBIT 22x LTM PE